Table of contents

  1. Front Matter
    Pages i-xvi
  2. Physiological Resistance

    1. Front Matter
      Pages 1-1
    2. Mark W. Dewhirst, Yiting Cao, Benjamin Moeller, Chuan-Yuan Li
      Pages 3-19
    3. Chang W. Song, Robert Griffin, Heon Joo Park
      Pages 21-42
    4. Sarah Jane Lunt, Richard P. Hill
      Pages 43-66
    5. Janusz W. Rak, Brenda Coomber, Joanne L. Yu
      Pages 67-103
    6. David A. Mankoff, Kenneth A. Krohn
      Pages 105-122
  3. Biological Resistance

    1. Front Matter
      Pages 123-123
    2. Ilia Mantle, Gabriela Dontu, Suling Liu, Max S. Wicha
      Pages 125-136
    3. William R. Waud
      Pages 137-150
    4. Anibal A. Arjona, Enrique Alvarez
      Pages 151-159
    5. Beverly A. Teicher
      Pages 161-179
    6. Vladislava O. Melnikova, Menashe Bar-Eli
      Pages 181-200
    7. Patrice J. Morin
      Pages 201-210
  4. Biochemical Resistance

    1. Front Matter
      Pages 211-211
    2. Victoria J. Findlay, Danyelle M. Townsend, Kenneth D. Tew
      Pages 213-221
    3. Faiyaz Notta, D. James Koropatnick
      Pages 223-239
    4. Susan E. Bates, John Deeken, Chaohong Fan, Robert W. Robey
      Pages 261-282
    5. Zahid H. Siddik
      Pages 283-307

About this book

Introduction

As genomic techniques gradually reveal the ability of malignant cells to respond to chemical and biological insults with remarkable flexibility of phenotype, it becomes clear that much remains to be done to control and eliminate such cells. In Cancer Drug Resistance, leading scientists from the best academic institutions and industrial laboratories summarize and synthesize the latest discoveries concerning the changes that occur in tumor cells as they develop resistance to a wide variety of anticancer therapeutics, as well as suggest new approaches to the biology of drug resistance that may afford new therapeutic opportunities. The authors review physiological resistance based tumor architecture, cellular resistance based on drug transport, epigenetic changes that neutralize or bypass drug cytotoxicity, and genetic changes that alter drug target molecules by decreasing or eliminating drug binding and efficacy. Highlights include new insights into resistance to antiangiogenic therapies, oncogenes and tumor suppressor genes in therapeutic resistance, cancer stem cells, and the development of more effective therapies. There are also new findings on tumor immune escape mechanisms, gene amplification in drug resistance, the molecular determinants of multidrug resistance, and resistance to taxanes and Herceptin®.
Authoritative and insightful, Cancer Drug Resistance offers basic and clinical investigators a state-of-the-art synthesis of the many faceted research now available on the biology and genetics of tumor resistance, as well as exciting new approaches to its prevention and eradication.

Keywords

angiogenesis cancer cytotoxicity drug drug resistance hormones imaging immunotherapy leukemia melanoma oncogenes pharmacology resistance toxicity tumor

Editors and affiliations

  • Beverly A. Teicher
    • 1
  1. 1.Genzyme CorporationFramingham

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-59745-035-5
  • Copyright Information Humana Press Inc. 2006
  • Publisher Name Humana Press
  • eBook Packages Medicine
  • Print ISBN 978-1-58829-530-9
  • Online ISBN 978-1-59745-035-5
  • About this book